سامانه جستجوی جامع منابع دانشگاه علوم پزشکی جندی شاپور اهواز



عنوان مجموعه اطلاعات : Faculty of 1000 evaluation for Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

ناشر : Faculty of 1000, Ltd.

DOI کد :

10.3410/f.732041227.793538598

سال انتشار : 2017

نویسنده : Nico van Zandwijk

نوع : مجموعه اطلاعات

لینک خروجی به مجموعه اطلاعات

@incollection{1,
    doi = {10.3410/f.732041227.793538598},
    url = {http://dx.doi.org/10.3410/f.732041227.793538598},
    year = 2017,
    publisher = {Faculty of 1000, Ltd.},
    pages = {},
    author = {Nico van Zandwijk},
    title = {Faculty of 1000 evaluation for Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.}
}
TY  - DATA
DO  - 10.3410/f.732041227.793538598
UR  - http://dx.doi.org/10.3410/f.732041227.793538598
TI  - Faculty of 1000 evaluation for Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
PY  - 2017
PB  - Faculty of 1000, Ltd.
SP  - 
AU  -Nico van Zandwijk
Nico van Zandwijk, T. (2017). Faculty of 1000 evaluation for Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.. doi:10.3410/f.732041227.793538598
“Faculty of 1000 evaluation for Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial..” (2017) - Author: Nico van Zandwijk